Literature DB >> 15009464

Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines.

W Pickering1, E Gray, A H Goodall, S Ran, P E Thorpe, T W Barrowcliffe.   

Abstract

The procoagulant activity (PCA) of four T-lymphoblastoid cell lines (CEM-CCRF, Jurkat, Molt-4 and A3.01) at different stages of differentiation has been characterized and compared with that of a monocytoid cell line (THP-1). Four assay systems were employed; the activated partial thromboplastin time (APTT); prothrombin time/tissue factor (TF) activity; a purified factor (F)Xa generation system and cancer procoagulant. High levels of TF activity were seen only with the monocytic cells. However the more differentiated of the T-lymphoblastoid cells (Molt-4 and A3.01) were more active than monocytic cells in supporting FXa generation. This pattern was not repeated for the APTT assay, which was related to cell-surface TF activity, since it was partially inhibited by antiTF antibody. Annexin V totally inhibited the activity observed in all three assay systems, indicating that the PCA of T-lymphoblastoid cells is primarily due to expression of negatively charged phospholipids. However, antiphosphatidylserine antibody even at a high concentration gave only partial inhibition of the activity observed in the APTT and FXa generation systems for the cells compared with almost total inhibition for the phospholipid standard, suggesting either that cellular phosphatidylserine (PS) is less accessible to the antibody, or that PS is not the sole negatively charged phospholipid responsible for this activity. Flow cytometry studies using propidium iodide and annexin V showed that the PCA, although linked to PS exposure, was not the result of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009464     DOI: 10.1111/j.1538-7836.2004.00607.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

1.  The role of carrier number on the procoagulant activity of tissue factor in blood and plasma.

Authors:  G W Tormoen; S Rugonyi; A Gruber; O J T McCarty
Journal:  Phys Biol       Date:  2011-11-02       Impact factor: 2.583

2.  Do circulating tumor cells play a role in coagulation and thrombosis?

Authors:  Garth W Tormoen; Kristina M Haley; Ross L Levine; Owen J T McCarty
Journal:  Front Oncol       Date:  2012-09-10       Impact factor: 6.244

3.  Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-κB/tissue factor/Factor Xa pathway in melanoma B16F10 cells.

Authors:  Yang Zhao; Daohai Zhang; Sheng Wang; Li Tao; Aiyun Wang; Wenxing Chen; Zhijie Zhu; Shizhong Zheng; Xiang Gao; Yin Lu
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

4.  Development of coagulation factor probes for the identification of procoagulant circulating tumor cells.

Authors:  Garth W Tormoen; Flor A Cianchetti; Paul E Bock; Owen J T McCarty
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

5.  Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

Authors:  Flávia Dias Xavier; Paulo Marcelo Gehm Hoff; Maria Ignez Braghiroli; Ana Carolina Carvalho Rocha Paterlini; Karla Teixeira Souza; Luiza Dib Batista Bugiato Faria; Fernando Sergio Blumm Ferreira; Karime Kalil Machado; Gustavo Dos Santos Fernandes
Journal:  J Glob Oncol       Date:  2016-06-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.